secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-09-24T23:59:59+00:00
Accession:  0001493152-25-014729
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology awarded $2.3M NIH grant for THIO-101 Phase 2 trial in NSCLC
------------------------------------------------------------------------------

- NIH grant of $2.3M supports expansion of THIO-101 Phase 2 trial evaluating ateganosine as third-line NSCLC treatment.
- Grant funds enrollment of US patients resistant to chemo/immunotherapy; distributed over 3 years (2025-2027).
- First US patient enrollment to begin immediately following 2023 FDA IND clearance; first expansion patient dosed July 2025 in Taiwan.
- Median overall survival for 22 third-line patients was 17.8 months (June 30, 2025) vs 5-6 months for standard chemo.
- Grant is non-dilutive funding from NIH's National Cancer Institute (Award R44CA309843).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225014729/0001493152-25-014729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225014729/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-014729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer